{{Rsnum
|rsid=61736512
|Gene=CYP2D6
|Chromosome=22
|position=42525134
|Orientation=plus
|GMAF=0.02984
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{PharmGKB
|RSID=rs61736512
|Name_s=CYP2D6: 1659G>A; 1747G>A
|Gene_s=CYP2D6
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp
|Annotation=This variant is part of the reduced functioning haplotype CYP2D6*29, which is found at an estimated allele frequency of 20% in African Tanzanians.
|Drugs=citalopram; codeine; desipramine; fluoxetine; fluvoxamine; gefitinib; haloperidol; imipramine; morphine; tramadol
|Drug Classes=
|Diseases=Cystic Fibrosis; Depression; Hypertension; Neoplasms; Pain; Parkinson Disease; Schizophrenia
|Curation Level=In-Depth
|PharmGKB Accession ID=PA162356063
}}

{{GET Evidence
|gene=CYP2D6
|aa_change=Val136Ile
|aa_change_short=V136I
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs61736512
|overall_frequency_n=272
|overall_frequency_d=10104
|overall_frequency=0.02692
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|nblosum100=-4
|autoscore=3
|webscore=N
|n_web_uneval=10
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}